SOMERSET, N.J.’ ’ Legend Biotech Corporation (NASDAQ: LEGN), a global leader in cell therapy, is poised to make significant strides in the treatment of multiple myeloma through groundbreaking data and strategic collaborations. The company recently announced several pivotal advancements, including new and updated data from their CARTITUDE clinical development program featuring CARVYKTI (ciltacabtagene autoleucel; cilta-cel) and a significant new licensing agreement with Novartis.CARTITUDE Clinical Development Program at ASCO and EHA 2024
Legend Biotech will present new and updated data from the CARTITUDE program at two of the most influential global medical conferences in 2024: the American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) Hybrid Congress. CARTITUDE, which evaluates the efficacy of CARVYKTI in treating multiple myeloma, has shown promising outcomes.
One of the highlights includes Cohort D’s data, which could provide new insights into how CARVYKTI performs in different patient populations. These presentations are anticipated to validate the effectiveness of CARVYKTI further and showcase Legend Biotech’s commitment to advancing CAR-T cell therapy.European Commission Approval for CARVYKTI
Adding another feather to its cap, Legend Biotech has achieved European Commission (EC) approval for CARVYKTI as a second-line treatment for adult patients with relapsed and refractory multiple myeloma. This approval is significant as it marks the therapy’s acceptance beyond its initial application setting. CARVYKTI is now authorized for patients who have received at least one prior line of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), and have shown disease progression.
The EC’s decision is expected to substantially impact the treatment paradigm for multiple myeloma in Europe, offering a new, effective treatment option for patients who have limited choices.Strategic License Agreement with Novartis for CAR-T Therapies Targeting DLL3
In another landmark move, Legend Biotech has closed an exclusive, worldwide license agreement with Novartis Pharma AG for certain CAR-T cell therapies targeting Delta-like ligand protein 3 (DLL3). This deal underscores Legend Biotech’s strategic expansion into developing and commercializing novel therapies to treat life-threatening diseases.
DLL3 is a promising target, primarily due to its expression in various malignancies, including small cell lung cancer and other neuroendocrine tumors. The partnership with Novartis aims to leverage both companies’ expertise and resources to expedite the development of these innovative therapies.Significance of These Developments
Legend Biotech’s recent achievements underline its leadership in the CAR-T cell therapy space. From presenting compelling new data at premier medical conferences to securing regulatory approvals and strategic partnerships, the company continues to push the envelope in cancer treatment, particularly for multiple myeloma.
CARVYKTI’s new EC approval as a second-line treatment widens its therapeutic horizon, potentially transforming current treatment protocols and improving patient outcomes. Meanwhile, the collaboration with Novartis for CAR-T therapies targeting DLL3 highlights Legend Biotech’s commitment to advancing next-generation therapies that can address diverse and unmet medical needs.
These advancements are not only milestones for Legend Biotech but also bear significant implications for the medical community and patients globally.
Comments